Melanoma antigens and related immunological markers

Pitcovski, Jacob; Shahar, Ehud; Aizenshtein, É. M.; Gorodetsky, Raphael

doi:10.1016/j.critrevonc.2017.05.001

Cited by 59 publications

(66 citation statements)

References 209 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, a modulation of tyrosinase may restore cancer cell sensitivity to chemotherapy by the depletion of pigment amount and increasing the concentration of unbound drug (Buitrago et al 2016). An important point is the fact that TYR expression is observed in nevi and in 80-90% of primary and metastatic melanomas, which makes it a useful diagnostic marker (Pitcovski et al 2017) as well as that decrease of tyrosinase amount is frequently observed and correlates with the MITF level (Hashemi-Shahri et al 2018, Lee et al 2015. In the present study, we observed a significant decrease of tyrosinase in C32 cells after prochlorperazine treatment only in concentration of 3 μM.…”

Section: Discussionsupporting

confidence: 54%

Antimelanoma activity of perphenazine and prochlorperazine in human COLO829 and C32 cell lines

Otręba

Pajor

Warncke

2019

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

Cutaneous melanoma is least common (only about 1% of skin cancers) but is the deadliest malignant tumor. Moreover, amelanotic types of melanoma are very difficult for clinical diagnosis. The standard therapy can cause a lot of side effects, e.g., nausea, vomiting, and headaches, which means that novel and effective strategies are required. Interestingly, phenothiazine derivatives possess sedative, antiemetic, and anticancer activity. Our goal was to determine the effect of perphenazine and prochlorperazine on cell viability, motility, microphthalmia-associated transcription factor (MITF) and tyrosinase content in melanotic and amelanotic melanoma cells. The viability of C32 and COLO829 melanoma cells was evaluated by the WST-1 colorimetric assay; impact on motility of human melanoma was performed by wound-healing assay, while tyrosinase and MITF content were determined by Western blot. In the present study, we explore the anticancer effect of perphenazine and prochlorperazine in human melanotic (COLO829) and amelanotic (C32) melanoma cells concluding that prochlorperazine inhibits cell viability in a concentration-dependent manner, impairs motility, and decreases tyrosinase and MITF amounts. Moreover, the analyzed drugs decrease/increase MITF amount depending on the type of melanoma. We demonstrated that the decrease of MITF and tyrosinase protein induces motility inhibition of C32 cells, which suggests the ability of those drugs to restore cancer cell sensitivity to treatment. The ability of prochlorperazine to contain the spread of the amelanotic melanoma in vivo may be helpful in the development of a new and effective antimelanoma therapies.

show abstract

Section: Discussionsupporting

confidence: 54%

Antimelanoma activity of perphenazine and prochlorperazine in human COLO829 and C32 cell lines

Otręba

Pajor

Warncke

2019

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

show abstract

“…TAAs are usually defined as peptides that are expressed, processed, and presented by tumor cells . While they may not be entirely tumor specific and may be expressed by nontumor cells, TAAs have the potential to facilitate the recognition of tumor cells by T lymphocytes . Importantly, targeted therapies have been shown to influence antitumor immunity by altering the expression of TAAs.…”

Section: Effects Of Targeted Therapies On Tumor Cells Relevant To Antmentioning

confidence: 99%

“…115 While they may not be entirely tumor specific and may be expressed by nontumor cells, TAAs have the potential to facilitate the recognition of tumor cells by T lymphocytes. 116 Importantly, targeted therapies have been shown to influence antitumor immunity by altering the expression of TAAs. For example, melanocyte differentiation antigens (MDAs) are TAAs derived from gene products (proteins) that play a role in melanocyte differentiation and as such can be expressed by melanoma cells.…”

Section: Antibody-mediated Effects From Therapeutic Monoclonal Antibomentioning

confidence: 99%

Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer

Kersh

Chang

et al. 2017

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Two pharmacologic approaches that are currently at the forefront of treating advanced cancer are those that center on disrupting critical growth/survival signaling pathways within tumor cells (commonly referred to as "targeted therapies") and those that center on enhancing the capacity of a patient's immune system to mount an antitumor response (immunotherapy). Maximizing responses to both of these approaches requires an understanding of the oncogenic events present in a given patient's tumor and the nature of the tumor-immune microenvironment. Although these 2 modalities were developed and initially used independently, combination regimens are now being tested in clinical trials, underscoring the need to understand how targeted therapies influence immunologic events. Translational studies and preclinical models have demonstrated that targeted therapies can influence immune cell trafficking, the production of and response to chemokines and cytokines, antigen presentation, and other processes relevant to antitumor immunity and immune homeostasis. Moreover, because these and other effects of targeted therapies occur in nonmalignant cells, targeted therapies are being evaluated for use in applications outside of oncology.

show abstract

“…Melanoma is a classic immunoresponsive solid tumor 12 . Several decades of melanoma research have produced an extensive set of research tools for studying tumor immunology in mice.…”

Section: Introductionmentioning

confidence: 99%

“…11 Melanoma is a classic immunoresponsive solid tumor. 12 Several decades of melanoma research have produced an extensive set of research tools for studying tumor immunology in mice. Many of these tools target glycoprotein 100 (gp100), which is found in normal melanocytes and is overexpressed in melanoma.…”

mentioning

confidence: 99%

Syngeneic murine model for prostate cancer using RM1 cells transfected with gp100

Yeon

Wang

et al. 2020

The Prostate

View full text Add to dashboard Cite

Background Prostate cancer (PC) is the most commonly diagnosed solid tumor in men. A major challenge in PC immunotherapy is the lack of an animal model that resembles human adenocarcinoma and allows for manipulation or monitoring of the immune response. Mouse models are needed for preclinical testing of new immunotherapies, whether used alone or in combination with established drugs, and to develop companion biomarkers that can be validated in clinical trials. Methods To develop a syngeneic prostate adenocarcinoma model with a well‐defined tumor antigen, murine RM1 PC cells were transfected with the endogenous mouse melanoma protein, gp100 (RM1‐gp100). Gp100 was attractive because it is a self‐protein and it instantly allowed us to use the large trove of immune research tools developed for melanoma research. A dendritic cell (DC) vaccine was used as model immunotherapy to demonstrate that adoptive immunotherapy against gp100 decreases the growth of RM1‐gp100 but not RM1. Results Expressing gp100 did not change the growth of RM1 cell in vitro or in vivo. The DCs pulsed with RM1‐gp100 could be used to stimulate Pmel‐1 lymphocyte proliferation and activation. Pmel‐1 lymphocytes could be adoptively transferred into C57Bl/6 mice that were treated with DCs pulsed with RM1‐gp100. The resulting Pmel‐1 lymphocytes were monitored to assess the primary cellular immune response and memory response. Conclusion We describe a murine model for prostate adenocarcinoma with a well‐characterized antigen that can be used in an immunologically intact mice to monitor the temporal CD8+ lymphocyte‐mediated antitumor immunity.

show abstract

Melanoma antigens and related immunological markers

Cited by 59 publications

References 209 publications

Antimelanoma activity of perphenazine and prochlorperazine in human COLO829 and C32 cell lines

Antimelanoma activity of perphenazine and prochlorperazine in human COLO829 and C32 cell lines

Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer

Syngeneic murine model for prostate cancer using RM1 cells transfected with gp100

Contact Info

Product

Resources

About